JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Protean Small Cap beat its benchmark in December. It returned 0.3%, while the index retracted by -0.1%. Click here to read ...

True, one of the drugmaker's leading candidates, CagriSema, recently failed to impress investors in a phase 3 study. Upon closer inspection, though, Novo Nordisk's "disappointing" late-stage ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

J.P. Morgan has once again picked Boston Scientific (NYSE:BSX) and Intuitive Surgical (NASDAQ:ISRG) as its top large-cap picks in MedTech for the new year, and reaffirmed insulin pump maker ...

GLP-1 drugs are known to have a direct effect on the endothelial cells that line blood vessels, lymph vessels and the heart, providing a biologically plausible mechanism for the cardiovascular benefit ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Healthcare & Pharmaceuticalscategory Lilly obesity drug Mounjaro to be offered in Britain's NHS after watchdog nod December 24, 2024 Healthcare & Pharmaceuticalscategory US FDA approves Hikma's ...